Rx Product News (August 2017)

SEPTEMBER 05, 2017

ORENCIA
MARKETED BY
: Bristol-Myers Squibb
INDICATION: The FDA has approved Orencia (abatacept) to treat adults with active psoriatic arthritis in both intravenous and subcutaneous injection formulations.
DOSAGE FORM: IV: 250 mg; injection: 50 mg/ 0.4 mL, 87.5 mg/0.7 mL, 125 mg/mL in single-dose prefilled syringes, or 125 mg/mL in a single-dose prefilled ClickJect autoinjector.
FOR MORE INFORMATION: bms.com


COTEMPLA XR-ODT
MARKETED BY
: Neos Therapeutics
INDICATION: The FDA has approved Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets to treat attention-deficit/hyperactivity disorder in patients aged 6 to 7 years.
DOSAGE FORM: Extended-release orally disintegrating tablets: 8.6 mg, 17.3 mg, and 25.9 mg
FOR MORE INFORMATION: neostx.com


RITUXAN HYCELA
MARKETED BY
: Genentech
INDICATION: The FDA approved Genentech’s rituximab/hyaluronidase (Rituxan Hycela) combination treatment for adult patients with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia. DOSAGE FORM: Injection
FOR MORE INFORMATION: gene.com


ENDARI
MARKETED BY
: Emmaus Medical, Inc.
INDICATION: The FDA has approved Endari (L-glutamine oral powder) to reduce the severe complications of sickle cell disease in adult and pediatric patients 5 years and older. DOSAGE FORM: Oral powder
FOR MORE INFORMATION: emmausmedical.com

SHARE THIS SHARE THIS
1725
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.